Announcement

Collapse
No announcement yet.

Article about Dr. Silver's injectable peptide

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Article about Dr. Silver's injectable peptide

    Probably nothing new but figured I would post it (https://www.biospace.com/article/inj...ts-walk-again/)

    Injectable Peptide Might Help Spinal Cord Injury Patients Walk Again
    A systemically injectable peptide, which may make it possible to restore lost functions in spinal cord injury patients, is moving toward clinical trials in early 2020.

    The treatment, which was developed by Jerry Silver, a professor of neurosciences at Case Western Reserve University?s School of Medicine and advisor for NervGen Pharma, is the culmination of decades of work, and in pre-clinical studies, it has shown robust results in animal models.
    Silver?s research has focused on why nerves are unable to regenerate. One key discovery, made 30 years ago, involved the critical role of a family of molecules called proteoglycans in nerve injury. During development of the brain and spinal cord, proteoglycans normally bind a receptor known as protein tyrosine phosphatase sigma (PTPσ) to help form proper synapses between neurons. Upon nerve injury, proteoglycans reappear within the scar, but because the severed nerve fibers make more of this same sticky receptor, they become forever entrapped within the scar, keeping them from regenerating. Silver hopes spinal cord injuries can be treated by overcoming these abnormal interactions between proteoglycans and the PTPσ receptor.
    ?You can think of the scar as flypaper to all cell types that have the receptor,? said Silver. ?The job of the scar is to create a bandage around the lesion, but in doing so it blocks regeneration.?

    The scar is important to wall off inflammation, so instead of trying to get rid of the scar, Silver?s work focused on allowing cells to free themselves from it. To do this, Silver?s lab developed Intracellular Sigma Peptide (ISP), which blocks PTPσ. With PTPσ blocked, cells with this receptor no longer see the proteoglycans, allowing them to regenerate the nerve fibers at the site of damage.


    Pre-clinical studies in rats have shown significant recoveries, with every animal showing improved bladder function and more than a third of animals regaining their ability to walk. This work has been independently replicated with an increased dosage, which showed even better recovery. Silver has also recently published results targeting the same signaling pathway that may provide similar promise for chronic spinal cord injury patients.
    Silver advises NervGen Pharma, which is working to bring NVG-291 ?a close analog of ISP used by Silver?s lab ? into the clinic. The Phase 1 clinical trial is expected to open in early 2020 and will test safety and dosing.

    While the current focus of NVG-291 is on spinal cord injuries, the applications may be much broader. If results from clinical trials involving NVG-291 are successful for spinal cord injury patients, the peptide might also be beneficial in treating several other debilitating conditions.
    ?The scar blocks growth in heart attacks after peripheral nerve injury or stroke, and in diseases such as multiple sclerosis and Alzheimer?s disease,? said Silver.
    Silver said the ISP in animal models showed no evidence of side effects such as pain or impaired mobility over the course of their treatment.
    While spinal cord injury patients will continue to need physical rehabilitation, the hope is that clinical trials will show that NVG-291 can improve the debilitating prognosis associated with this kind of injury.


    Almost 200,000 Americans have spinal cord injuries, with an estimated 17,000 new injuries each year. More than a million Americans have a debilitating peripheral nerve injury, and many others experience additional issues related to nerve damage and tissue scarring.

    #2
    Has anyone reached out to Jerry about this? Any idea regarding what type of results to expect from this trial?

    If I'm reading the above correctly, it sounds like this peptide may allow nerves to bypass the scar.
    No one ever became unsuccessful by helping others out

    Comment


      #3
      canadian big pharma biotech co bought it and has it by the balls now.
      "Talk without the support of action means nothing..."
      ― DaShanne Stokes

      ***Unite(D) to Fight Paralyses***

      Comment


        #4
        Originally posted by Moe View Post
        canadian big pharma biotech co bought it and has it by the balls now.
        Is this a good thing?

        Comment


          #5
          Originally posted by Moe View Post
          canadian big pharma biotech co bought it and has it by the balls now.
          Do you know which Pharma purchased the technology? If it's NervGen, that's the company that Jerry is an advisor for.

          I think, in that case, it would be a great thing.

          For those further interested,

          -here is the url for the pharmaceutical company: https://www.nervgen.com/

          -for those who would like to purchase a piece of the company, the stock ticker is 'NGENF'. It's trading at around $1.11 - $1.15 per share.
          Last edited by Tufelhunden; 11 Jul 2019, 12:30 AM. Reason: Included more information pertaining to NervGen
          No one ever became unsuccessful by helping others out

          Comment


            #6
            NerveGen is not Canadian Big Pharma. NerveGen is a startup. Two very different things.

            Comment


              #7
              And you can add the fact that those involved in initiating the startup company have a direct connection to spinal cord injury.
              http://spinalcordresearchandadvocacy.wordpress.com/

              Comment


                #8
                Originally posted by Fly_Pelican_Fly View Post
                NerveGen is not Canadian Big Pharma. NerveGen is a startup. Two very different things.
                Just checked NervGen's website; seems it still has this peptide in its portfolio.
                No one ever became unsuccessful by helping others out

                Comment


                  #9
                  I'll get excited if they ever do human trials. To me so far the hype is based on rats and the propaganda is to boost stock market share sales. Reminds me of Geron back in 2010... will probably experience the same fate, just to lye around on a shelf as a media attention getter... get shareholders exited to buy/sell till it dies...
                  Last edited by Moe; 30 Jul 2019, 7:44 PM.
                  "Talk without the support of action means nothing..."
                  ― DaShanne Stokes

                  ***Unite(D) to Fight Paralyses***

                  Comment


                    #10
                    Originally posted by Moe View Post
                    I'll get excited if they ever do human trials. To me so far the hype is based on rats and the propaganda is to boost stock market share sales. Reminds me of Geron back in 2010... will probably experience the same fate, just to lye around on a shelf as a media attention getter... get shareholders exited to buy/sell till it dies...
                    Man, I hope you're wrong. I wonder if anyone knows the guy and can reach out and see if he has any information available to share.
                    No one ever became unsuccessful by helping others out

                    Comment


                      #11
                      Originally posted by Moe View Post
                      I'll get excited if they ever do human trials. To me so far the hype is based on rats and the propaganda is to boost stock market share sales. Reminds me of Geron back in 2010... will probably experience the same fate, just to lye around on a shelf as a media attention getter... get shareholders exited to buy/sell till it dies...
                      I'd suggest you are complaining about the wrong thing. The fact that this has only been approved on acute models, and never on chronic (someone please tell me I'm wrong), is the problem. We read the hype and start hoping, but it will never be useful for us.

                      Comment


                        #12
                        Originally posted by niallel View Post
                        I'd suggest you are complaining about the wrong thing. The fact that this has only been approved on acute models, and never on chronic (someone please tell me I'm wrong), is the problem. We read the hype and start hoping, but it will never be useful for us.
                        I'm sorry, I think you missed my point. also I wasn't aware that Its been aprooved to the public market to human acutes? Thoght is was just a trial that died on a shelf over the years...
                        "Talk without the support of action means nothing..."
                        ― DaShanne Stokes

                        ***Unite(D) to Fight Paralyses***

                        Comment


                          #13
                          Originally posted by Moe View Post
                          I'm sorry, I think you missed my point. also I wasn't aware that Its been aprooved to the public market to human acutes? Thoght is was just a trial that died on a shelf over the years...
                          Sorry, it was a typo I meant proved.

                          Comment

                          Working...
                          X